DGX Quote, Financials, Valuation and Earnings

Danaher has a net margin of 8.3% compared to Quest Diagnostics's net margin of 16.62%. Quest Diagnostics's return on equity of 13.14% beat Danaher's return on equity of 7.38%.

Quest Diagnostics has a consensus price target of $183.92, signalling upside risk potential of 2.73%. On the other hand Danaher has an analysts' consensus of $247.14 which suggests that it could grow by 20.5%. Given that Danaher has higher upside potential than Quest Diagnostics, analysts believe Danaher is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.488, which suggesting that the stock is 51.246% less volatile than S&P 500. In comparison Danaher has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.765%.

Quest Diagnostics has a quarterly dividend of $0.80 per share corresponding to a yield of 1.7%. Danaher offers a yield of 0.55% to investors and pays a quarterly dividend of $0.32 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Danaher pays out 19.7% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.7B, which are smaller than Danaher quarterly revenues of $5.7B. Quest Diagnostics's net income of $220M is lower than Danaher's net income of $954M. Notably, Quest Diagnostics's price-to-earnings ratio is 22.63x while Danaher's PE ratio is 39.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 2.00x versus 6.29x for Danaher. Usually stocks with elevated PS ratios are considered overvalued.

Guardant Health has a net margin of 8.3% compared to Quest Diagnostics's net margin of -46.77%. Quest Diagnostics's return on equity of 13.14% beat Guardant Health's return on equity of -8518.58%.

Quest Diagnostics has a consensus price target of $183.92, signalling upside risk potential of 2.73%. On the other hand Guardant Health has an analysts' consensus of $59.43 which suggests that it could grow by 21.25%. Given that Guardant Health has higher upside potential than Quest Diagnostics, analysts believe Guardant Health is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.488, which suggesting that the stock is 51.246% less volatile than S&P 500. In comparison Guardant Health has a beta of 1.373, suggesting its more volatile than the S&P 500 by 37.333%.

Quest Diagnostics has a quarterly dividend of $0.80 per share corresponding to a yield of 1.7%. Guardant Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Guardant Health pays out -- of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.7B, which are larger than Guardant Health quarterly revenues of $203.5M. Quest Diagnostics's net income of $220M is higher than Guardant Health's net income of -$95.2M. Notably, Quest Diagnostics's price-to-earnings ratio is 22.63x while Guardant Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 2.00x versus 7.81x for Guardant Health. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings has a net margin of 8.3% compared to Quest Diagnostics's net margin of 6.36%. Quest Diagnostics's return on equity of 13.14% beat Labcorp Holdings's return on equity of 9.01%.

Quest Diagnostics has a consensus price target of $183.92, signalling upside risk potential of 2.73%. On the other hand Labcorp Holdings has an analysts' consensus of $274.62 which suggests that it could grow by 4.96%. Given that Labcorp Holdings has higher upside potential than Quest Diagnostics, analysts believe Labcorp Holdings is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.488, which suggesting that the stock is 51.246% less volatile than S&P 500. In comparison Labcorp Holdings has a beta of 0.812, suggesting its less volatile than the S&P 500 by 18.757%.

Quest Diagnostics has a quarterly dividend of $0.80 per share corresponding to a yield of 1.7%. Labcorp Holdings offers a yield of 1.1% to investors and pays a quarterly dividend of $0.72 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Labcorp Holdings pays out 32.59% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.7B, which are smaller than Labcorp Holdings quarterly revenues of $3.3B. Quest Diagnostics's net income of $220M is higher than Labcorp Holdings's net income of $212.8M. Notably, Quest Diagnostics's price-to-earnings ratio is 22.63x while Labcorp Holdings's PE ratio is 30.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 2.00x versus 1.67x for Labcorp Holdings. Usually stocks with elevated PS ratios are considered overvalued.

RadNet has a net margin of 8.3% compared to Quest Diagnostics's net margin of -8.05%. Quest Diagnostics's return on equity of 13.14% beat RadNet's return on equity of -2.91%.

Quest Diagnostics has a consensus price target of $183.92, signalling upside risk potential of 2.73%. On the other hand RadNet has an analysts' consensus of $71.57 which suggests that it could grow by 27.25%. Given that RadNet has higher upside potential than Quest Diagnostics, analysts believe RadNet is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.488, which suggesting that the stock is 51.246% less volatile than S&P 500. In comparison RadNet has a beta of 1.429, suggesting its more volatile than the S&P 500 by 42.944%.

Quest Diagnostics has a quarterly dividend of $0.80 per share corresponding to a yield of 1.7%. RadNet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics pays 38% of its earnings as a dividend. RadNet pays out -- of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.7B, which are larger than RadNet quarterly revenues of $471.4M. Quest Diagnostics's net income of $220M is higher than RadNet's net income of -$37.9M. Notably, Quest Diagnostics's price-to-earnings ratio is 22.63x while RadNet's PE ratio is 1,513.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 2.00x versus 2.30x for RadNet. Usually stocks with elevated PS ratios are considered overvalued.